Traitement par anticorps anti-IgE de l’asthme allergique difficile à contrôler
- 31 December 2005
- journal article
- review article
- Published by Elsevier BV in Revue des Maladies Respiratoires
- Vol. 22 (6), 983-990
- https://doi.org/10.1016/s0761-8425(05)85729-8
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Immunoglobuline E et maladies respiratoiresRevue des Maladies Respiratoires, 2005
- Anti‐immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti‐inflammatory activity and clinical efficacyClinical & Experimental Allergy, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy, 2004
- Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2004
- The pharmacological basis of anti-IgE therapyNature Biotechnology, 2000
- The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differencesImmunology Today, 1999
- Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitisJournal of Allergy and Clinical Immunology, 1997
- The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.American Journal of Respiratory and Critical Care Medicine, 1997
- The human IgE networkNature, 1993